Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A Two-year Open-label Single-arm Study of Teriparatide in Secondary Care
Phase of Trial: Phase IV
Latest Information Update: 11 May 2017
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.
- 12 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to the results published.